

## **Supplementary Material**

### **Full eligibility criteria**

#### **1. Inclusion criteria**

Patients were eligible for the study when they met all of the following inclusion criteria:

(1) Between 20 and 80 years of age. (2) Newly diagnosed or relapsed gynecologic cancer (epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, cervical cancer, or uterine corpus cancer). (3) Appropriate for paclitaxel and carboplatin combination therapy. (4) Eastern Cooperative Oncology Group (ECOG) performance grade 0-2. (5) Adequate blood, liver, and kidney function upon screening within 14 days before starting study treatment. The patients must meet the following requirements: absolute neutrophil count  $\geq 1.5 \times 10^9/L$ , hemoglobin  $\geq 10$  g/dl, platelet count  $\geq 100 \times 10^9/L$ , serum alkaline phosphatase  $\leq 2.5 \times$  upper limits of normal (ULN), serum aspartate aminotransferase and alanine aminotransferase  $\leq 2.5 \times$  ULN, and serum creatinine  $\leq 1.5 \times$  ULN. (6) written informed consent provided before participation.

#### **2. Exclusion criteria**

Patients were excluded if they met any of the following exclusion criteria:

(1) History of carcinoma other than gynecologic cancer in the past five years. (2) Received radiotherapy in the pelvis or abdominal cavity. (3) Received hormone therapy or immunotherapy for gynecologic cancer. (4) Received a major operation other than debulking for gynecologic cancer within 2 weeks before the screening. (5) History of central nervous system metastases. (6) National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE ver. 4.0) grade  $\geq 1$  sensory or motor neuropathy. (7) Uncontrolled comorbidities, including psychiatric illness that prevented understanding of the study and providing informed consent, active infectious disease, severe cardiovascular disease, or hypersensitivity to any of the study drugs or the vehicle. (8) Participated in another clinical trial in the last 4 weeks before the screening. (9) Pregnant or breastfeeding patients or those of childbearing potential who have not used medically acceptable contraceptive methods.